<<  Heinrich Heine die grte deutsche Dichter Hip-Hop and Rap  >>
Hematopoietic and Lymphoid Neoplasm Project
Hematopoietic and Lymphoid Neoplasm Project
Background
Background
Objectives (1)
Objectives (1)
Objectives (2)
Objectives (2)
Why New Rules
Why New Rules
Hematopoietic Working Group (1) Led by NCI SEER
Hematopoietic Working Group (1) Led by NCI SEER
Hematopoietic Working Group (2)
Hematopoietic Working Group (2)
Working Group Objectives
Working Group Objectives
What is New / Different
What is New / Different
What is New / Different
What is New / Different
What is New / Different
What is New / Different
Manual & Database
Manual & Database
Manual (Rules) Reportability Multiple primary Primary site & histology
Manual (Rules) Reportability Multiple primary Primary site & histology
14
14
Case Reportability and Coding Manual Glossary
Case Reportability and Coding Manual Glossary
Appendix A History of Hematopoietic and Lymphoid Neoplasm Coding
Appendix A History of Hematopoietic and Lymphoid Neoplasm Coding
Table A2: Hodgkin Lymphoma (Hodgkin Disease) Obsolete Terms
Table A2: Hodgkin Lymphoma (Hodgkin Disease) Obsolete Terms
Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid
Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid
Table B1: Myeloproliferative Neoplasms
Table B1: Myeloproliferative Neoplasms
Appendix C Lymph Node/Lymph Node Chain Reference Table
Appendix C Lymph Node/Lymph Node Chain Reference Table
Table C1: Lymph Node / Lymph Node Chain Reference Table
Table C1: Lymph Node / Lymph Node Chain Reference Table
Appendix D New Histology Terms and Codes Hematopoietic and Lymphoid
Appendix D New Histology Terms and Codes Hematopoietic and Lymphoid
Tables D1a & D1b New Histology Terms and Codes
Tables D1a & D1b New Histology Terms and Codes
Table D2: Histologic Terms and Codes with Changes in Case
Table D2: Histologic Terms and Codes with Changes in Case
Appendix E Histology NOS Tables
Appendix E Histology NOS Tables
Table E1: ICD-O-3 NOS Terms and Codes and WHO New NOS Terms and
Table E1: ICD-O-3 NOS Terms and Codes and WHO New NOS Terms and
Appendix F Master Code Lists
Appendix F Master Code Lists
Table F1a: WHO/ICD-O-3 Master List of Histology Codes  Alphabetical
Table F1a: WHO/ICD-O-3 Master List of Histology Codes Alphabetical
Summary
Summary
Conclusion
Conclusion

: Hematopoietic and Lymphoid Neoplasm Project. : NCI SEER. : Hematopoietic and Lymphoid Neoplasm Project.ppt. zip-: 925 .

Hematopoietic and Lymphoid Neoplasm Project

Hematopoietic and Lymphoid Neoplasm Project.ppt
1 Hematopoietic and Lymphoid Neoplasm Project

Hematopoietic and Lymphoid Neoplasm Project

2 Background

Background

Peggy Adamo, RHIT, CTR NCI SEER September 2009

3 Objectives (1)

Objectives (1)

Explain why rules were developed Describe Hematopoietic working group General information Membership Objectives

3

4 Objectives (2)

Objectives (2)

Introduce products developed Manual (Rules) Database Explain why two products were needed

4

5 Why New Rules

Why New Rules

Under-reporting of hem/lymph cases Medical advances New terminology Revised WHO Classification of Hem Tumors Abbreviated reporting rules Lack of documentation covering all neoplasms

5

6 Hematopoietic Working Group (1) Led by NCI SEER

Hematopoietic Working Group (1) Led by NCI SEER

Representatives from

National Cancer Registrars Association (NCRA) North American Association of Central Cancer Registries (NAACCR) Canadian Cancer Registries (CCR)

National Program of Cancer Registries Centers for Disease Control (NPCR CDC) American College of Surgeons Commission on Cancer (ACoS CoC)

6

7 Hematopoietic Working Group (2)

Hematopoietic Working Group (2)

Membership includes Hospital registrars Central registry registrars Specialty physicians Pathologists

7

8 Working Group Objectives

Working Group Objectives

Define problems Recommend actions Develop solutions to support cancer registrars Improve data quality

8

9 What is New / Different

What is New / Different

(1)

Authoritative reference = WHO New histology terms Transformation = new primary

9

10 What is New / Different

What is New / Different

(2)

Manual Covers all hematopoietic and lymphoid neoplasms

10

11 What is New / Different

What is New / Different

(3)

Database Replaces Single Versus Subsequent Primaries of Lymphatic and Hematopoietic Diseases table Replaces previous casefinding & reportable lists

11

12 Manual & Database

Manual & Database

Designed to work together Use database in conjunction with manual

12

13 Manual (Rules) Reportability Multiple primary Primary site & histology

Manual (Rules) Reportability Multiple primary Primary site & histology

Grade Glossary Tables

Database Definition Synonyms Definitive diagnostic method Transformations Abstractor notes Treatment types Genetic testing & immunophenotyping MP calculator

13

14 14

14

15 Case Reportability and Coding Manual Glossary

Case Reportability and Coding Manual Glossary

Allogeneic bone marrow/stem cell transplant: Marrow is used from a donor whose Human Leukocyte Antigens (HLA) Anemia: The number of red blood cells is below normal Apheresis: Process in which the blood of a donor or patient BCR-ABL cancer gene: A mutant gene that is formed

15

16 Appendix A History of Hematopoietic and Lymphoid Neoplasm Coding

Appendix A History of Hematopoietic and Lymphoid Neoplasm Coding

Obsolete terms as defined in ICD-O-3 Hematopoietic and Lymphoid Neoplasms

16

17 Table A2: Hodgkin Lymphoma (Hodgkin Disease) Obsolete Terms

Table A2: Hodgkin Lymphoma (Hodgkin Disease) Obsolete Terms

Obsolete Term

Notes

ICD-O-3 Code

Current Term

Hodgkin disease, lymphocyte predominance, diffuse

9651/3

Lymphocyte-rich Hodgkin lymphoma

Hodgkin disease, lymphocyte predominance, NOS

9651/3

Lymphocyte-rich Hodgkin lymphoma

Hodgkin disease, lymphocytic-histiocytic predominance

9651/3

Lymphocyte-rich Hodgkin lymphoma

Source: Lukes-Butler classification, 1966; Obsolete: REAL classification 1994

Source : Rye classification, 1966 ; Obsolete : REAL classification 1994

Source: Lukes-Butler classification, 1966; Obsolete as of REAL classification 1994

17

18 Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid

Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid

Tissues Histology Lineage

Note: Only the WHO Preferred Terms are listed. Use the Hematopoietic Database to identify synonyms that correspond to the WHO Preferred Term

18

19 Table B1: Myeloproliferative Neoplasms

Table B1: Myeloproliferative Neoplasms

WHO Preferred Term

ICD-O- 3

Chronic eosinophilic leukemia, NOS

9964/3

Chronic myelogenous leukemia, BCR-ABL1 positive

9875/3

Chronic neutrophilic leukemia

9963/3

Cutaneous mastocytosis

9740/1

Essential thrombocythemia

9962/3

Mast cell leukemia

9742/3

Mast cell sarcoma

9740/3

Myeloproliferative neoplasm, unclassifiable

9975/3

Polycythemia vera

9950/3

Primary myelofibrosis

9961/3

Systemic mastocytosis

9741/3

19

20 Appendix C Lymph Node/Lymph Node Chain Reference Table

Appendix C Lymph Node/Lymph Node Chain Reference Table

20

21 Table C1: Lymph Node / Lymph Node Chain Reference Table

Table C1: Lymph Node / Lymph Node Chain Reference Table

Lymph Node / Lymph Node Chain

ICD-O-3 Code

ICD-O-3 Lymph Node Region(s)

AJCC Lymph Node Region(s)

Abdominal

C772

Intra-abdominal

Pelvic, right and left*

Anorectal

C772

Intra-abdominal

Pelvic, right and left*

Anterior axillary

C773

Axilla or arm

Axillary, right and left*

Anterior cecal

C772

Intra-abdominal

Para-aortic

Anterior deep cervical

C770

Head, face and neck

Cervical, right and left*

Anterior jugular

C770

Head, face and neck

Cervical, right and left*

Aortic NOS; ascending aortic lateral aortic; lumbar aortic; para-aortic; peri-aortic

C772

Intra-abdominal

Para-aortic

21

22 Appendix D New Histology Terms and Codes Hematopoietic and Lymphoid

Appendix D New Histology Terms and Codes Hematopoietic and Lymphoid

Neoplasms

22

23 Tables D1a & D1b New Histology Terms and Codes

Tables D1a & D1b New Histology Terms and Codes

New Histology Term

ICD-O Code

Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1

9911/3

Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1EVI1

9869/3

Acute myeloid leukemia with t(6;9)(p23;q34) DEK-NUP214

9865/3

ALK positive large B-cell lymphoma

9737/3

B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)

9814/3

B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1

9812/3

B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged

9813/3

23

24 Table D2: Histologic Terms and Codes with Changes in Case

Table D2: Histologic Terms and Codes with Changes in Case

Reportability (Newly Reportable Conditions)

Histology Term

ICD-O Code

Langerhans cell histiocytosis, NOS

9751/3

Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable

9975/3

T-cell large granular lymphocytic leukemia/ Chronic lymphoproliferative disorder of NK-cells

9831/3

24

25 Appendix E Histology NOS Tables

Appendix E Histology NOS Tables

25

26 Table E1: ICD-O-3 NOS Terms and Codes and WHO New NOS Terms and

Table E1: ICD-O-3 NOS Terms and Codes and WHO New NOS Terms and

Codes Alphabetic List

Term

Reference

Code

Malignant lymphoma, NOS

ICD-O

9590/3

Malignant lymphoma, non-Hodgkin, NOS

ICD-O

9591/3

Hodgkin lymphoma, NOS

ICD-O

9650/3

Burkitt lymphoma, NOS

ICD-O

9687/3

Mixed phenotype acute leukemia, B/myeloid, NOS

WHO

9808/3

Mixed phenotype acute leukemia, T/myeloid, NOS

WHO

9809/3

B lymphoblastic leukemia/lymphoma, NOS

WHO

9811/3

26

27 Appendix F Master Code Lists

Appendix F Master Code Lists

27

28 Table F1a: WHO/ICD-O-3 Master List of Histology Codes  Alphabetical

Table F1a: WHO/ICD-O-3 Master List of Histology Codes Alphabetical

List

Histologic Term

2010 WHO Only

ICD-O-3 Only

WHO and ICD-O-3

Acute basophilic leukemia

9870/3

Acute biphenotypic leukemia

9805/3

Acute erythroid leukemia

9840/3

Acute megakaryoblastic leukemia

9910/3

Acute monoblastic and monocytic leukemia

9891/3

Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-1

9911/3

28

29 Summary

Summary

Reason rules were developed Describe Hematopoietic working group Introduce Manual & Database Reason for two products

29

30 Conclusion

Conclusion

The new hematopoietic and lymphoid neoplasm rules go into effect for cases diagnosed January 1, 2010, and after Email address for questions askseerctr@imsweb.com

30

Hematopoietic and Lymphoid Neoplasm Project
http://900igr.net/prezentacija/anglijskij-jazyk/hematopoietic-and-lymphoid-neoplasm-project-121749.html
c

661

29
900igr.net > > > Hematopoietic and Lymphoid Neoplasm Project